INT156739

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.75
First Reported 2007
Last Reported 2008
Negated 0
Speculated 0
Reported most in Body
Documents 2
Total Number 6
Disease Relevance 3.21
Pain Relevance 0.03

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell differentiation (SRY) nucleus (SRY) DNA binding (SRY)
transcription factor binding (SRY) cytoplasm (SRY)
Anatomy Link Frequency
lung 1
SRY (Homo sapiens)
Pain Link Frequency Relevance Heat
Bioavailability 10 56.36 Quite High
Pain 4 50.00 Quite Low
Morphine 2 50.00 Quite Low
headache 5 37.64 Quite Low
Potency 20 10.04 Low Low
peripheral neuropathy 5 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Acquired Immune Deficiency Syndrome Or Hiv Infection 180 94.08 High High
Hepatitis B Virus Infection 55 90.28 High High
Hepatitis 15 85.08 High High
Lung Cancer 2 81.48 Quite High
Pain 2 79.92 Quite High
Toxicity 80 78.72 Quite High
Infection 15 78.60 Quite High
Lipodystrophy 20 73.28 Quite High
Liver Disease 5 67.96 Quite High
Sprains And Strains 15 60.40 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Because both TDF and FTC are excreted via the kidneys, modification of TDF-FTC dosage and special caution is necessary when treating patients with renal impairments (Table 3) (Gilead Sciences 2006; Bartlett and Gallant 2005).
Localization (excreted) of TDF
1) Confidence 0.75 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2387297 Disease Relevance 0.55 Pain Relevance 0
TDF-FTC is excreted in breast milk and should not be used while nursing (Gilead Sciences 2006).
Localization (excreted) of TDF
2) Confidence 0.65 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2387297 Disease Relevance 1.12 Pain Relevance 0
Therapeutic use of TDF-FTC among special populations
Localization (use) of TDF
3) Confidence 0.61 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2387297 Disease Relevance 0.28 Pain Relevance 0
K65R can be selected by TDF as well as the NRTIs abacavir and didanosine.
Localization (selected) of TDF
4) Confidence 0.61 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2387297 Disease Relevance 0.78 Pain Relevance 0
Other once-a-day NRTI combinations include fixed-dose abacavir + lamivudine (EpzicomĀ®) and didanosine with either TDF or stavudine (D4T) extended release.
Localization (release) of TDF
5) Confidence 0.61 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2387297 Disease Relevance 0.32 Pain Relevance 0.03
MATERIAL-METHODS: According to three step analgesic guidelines recommended by the World Health Organization, 50 chronic lung cancer patients requiring third line therapy were enrolled and received either TDF patch (Grup F, n=25) or SRM per orally (Grup M, n=25) for 15 days.
Localization (received) of TDF in lung
6) Confidence 0.09 Published 2008 Journal Agri Section Body Doc Link 19085178 Disease Relevance 0.16 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox